PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
752.87%
Operating expenses growth above 1.5x AXSM's 6.62%. Michael Burry would check for inefficiency.
752.87%
Total costs growth above 1.5x AXSM's 8.31%. Michael Burry would check for inefficiency.
22.99%
Similar interest expense growth to AXSM's 24.56%. Walter Schloss would investigate norms.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
675.86%
Tax expense change of 675.86% while AXSM maintains burden. Bruce Berkowitz would investigate strategy.
-675.86%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-2175.00%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-2175.00%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-66.67%
Share count reduction while AXSM shows 1.17% change. Joel Greenblatt would examine strategy.
-66.67%
Diluted share reduction while AXSM shows 1.17% change. Joel Greenblatt would examine strategy.